JPH075457B2
(ja)
*
|
1983-08-16 |
1995-01-25 |
ザ ウエルカム フアウンデ−シヨン リミテツド |
調節された方法による有効成分の放出を可能にする医薬組成物
|
US4600773A
(en)
*
|
1983-12-01 |
1986-07-15 |
Eli Lilly And Company |
Crystalline cephalexin hydrochloride monohydrate
|
US4624847A
(en)
*
|
1985-04-22 |
1986-11-25 |
Alza Corporation |
Drug delivery device for programmed delivery of beneficial drug
|
ES8800043A1
(es)
*
|
1985-08-16 |
1987-10-16 |
Alza Corp |
Un dispositivo distribuidor para descargar una formulacion de agente beneficioso a un entorno de uso
|
US4963141A
(en)
*
|
1985-08-16 |
1990-10-16 |
Alza Corporation |
Dispensing system for administering beneficial agent formulation to ruminants
|
US4704118A
(en)
*
|
1985-08-16 |
1987-11-03 |
Alza Corporation |
Ruminant dispensing device with thermo-activated memory
|
US4723957A
(en)
*
|
1986-02-07 |
1988-02-09 |
Alza Corp. |
System for delivering drug with enhanced bioacceptability
|
US4716496A
(en)
*
|
1986-05-09 |
1987-12-29 |
Eaton Corporation |
Panel-mounted control station housing
|
US4814181A
(en)
*
|
1987-09-03 |
1989-03-21 |
Alza Corporation |
Dosage form comprising fast agent delivery followed by slow agent delivery
|
US4816263A
(en)
*
|
1987-10-02 |
1989-03-28 |
Alza Corporation |
Dosage form for treating cardiovascular diseases comprising isradipine
|
EP0317780B1
(en)
*
|
1987-11-25 |
1992-05-20 |
American Cyanamid Company |
Sustained (controlled) release delivery system for substituted dihydropyridine calcium channel blockers
|
US4837111A
(en)
*
|
1988-03-21 |
1989-06-06 |
Alza Corporation |
Dosage form for dispensing drug for human therapy
|
US4855141A
(en)
*
|
1988-03-25 |
1989-08-08 |
Alza Corporation |
Device comprising means for protecting and dispensing fluid sensitive medicament
|
US4859470A
(en)
*
|
1988-06-02 |
1989-08-22 |
Alza Corporation |
Dosage form for delivering diltiazem
|
US5612059A
(en)
*
|
1988-08-30 |
1997-03-18 |
Pfizer Inc. |
Use of asymmetric membranes in delivery devices
|
IL91398A
(en)
*
|
1988-08-30 |
1994-05-30 |
Pfizer |
A device for the controlled release of pneumatic substances, including the active substance, surrounded by an asymmetric membrane
|
GR1000270B
(el)
*
|
1988-09-30 |
1992-05-12 |
Alza Corp |
Μορφη δοσολογιας για θεραπεια καρδιαγγειακων ασθενειων.
|
IL92966A
(en)
*
|
1989-01-12 |
1995-07-31 |
Pfizer |
Hydrogel-operated release devices
|
US5108756A
(en)
*
|
1989-01-12 |
1992-04-28 |
Pfizer Inc. |
Dispensing devices powered by lyotropic liquid crystals
|
US5030452A
(en)
*
|
1989-01-12 |
1991-07-09 |
Pfizer Inc. |
Dispensing devices powered by lyotropic liquid crystals
|
EP0408496A3
(en)
*
|
1989-07-12 |
1992-07-01 |
Ciba-Geigy Ag |
Solid dosage form for pharmaceutical substances
|
US4992277A
(en)
*
|
1989-08-25 |
1991-02-12 |
Schering Corporation |
Immediate release diltiazem formulation
|
US5000962A
(en)
*
|
1989-08-25 |
1991-03-19 |
Schering Corporation |
Long acting diltiazem formulation
|
US5067960A
(en)
*
|
1989-12-06 |
1991-11-26 |
Medtronic, Inc. |
Muscle fitness detection by colorimetry
|
US5190763A
(en)
*
|
1990-05-07 |
1993-03-02 |
Alza Corporation |
Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
|
US5081161A
(en)
*
|
1990-06-15 |
1992-01-14 |
E. I. Du Pont De Nemours And Company |
Process for making shaped articles of a thermoplastic resin having a microcellular structure
|
NZ238867A
(en)
*
|
1990-07-12 |
1993-08-26 |
Alza Corp |
Dosage form for delayed release comprising pharmaceutically active substance and a drug-release hindering means and a second composition which imbibes fluid, expands, and ejects the active substance from the device
|
DK0542926T3
(da)
*
|
1990-08-07 |
1995-05-15 |
Pfizer |
Brug af grænsefladepolymeriserede membraner i frigivelsesanordninger
|
US5166145A
(en)
*
|
1990-09-10 |
1992-11-24 |
Alza Corporation |
Antiemetic therapy
|
DK0550641T3
(da)
*
|
1990-09-28 |
1994-08-22 |
Pfizer |
Dispenseringsanordning indeholdende et hydrofobt medium
|
US5208037A
(en)
*
|
1991-04-22 |
1993-05-04 |
Alza Corporation |
Dosage forms comprising polymers comprising different molecular weights
|
DK0612519T3
(da)
*
|
1993-02-23 |
2001-08-06 |
Wolfgang Dr Werner |
Anvendelse af et calciumpræparat i et medikament til terapeutisk anvendelse på malkekøer, der lider af hypocalcaemia
|
US6440457B1
(en)
*
|
1993-05-27 |
2002-08-27 |
Alza Corporation |
Method of administering antidepressant dosage form
|
US6287598B1
(en)
*
|
1993-05-28 |
2001-09-11 |
Alza Corporation |
Method for providing sustained antiepileptic therapy
|
HU213407B
(en)
*
|
1993-12-09 |
1997-06-30 |
Egyt Gyogyszervegyeszeti Gyar |
Process for producing tablet with diffusive-osmotic release
|
US5460826A
(en)
*
|
1994-06-27 |
1995-10-24 |
Alza Corporation |
Morphine therapy
|
US5948787A
(en)
*
|
1997-02-28 |
1999-09-07 |
Alza Corporation |
Compositions containing opiate analgesics
|
DE19962924A1
(de)
|
1999-12-24 |
2001-07-05 |
Bayer Ag |
Substituierte Oxazolidinone und ihre Verwendung
|
JP2004512354A
(ja)
*
|
2000-10-30 |
2004-04-22 |
ユーロ−セルティーク,エス.エイ. |
ヒドロコドン放出制御製剤
|
US20110104214A1
(en)
|
2004-04-15 |
2011-05-05 |
Purdue Pharma L.P. |
Once-a-day oxycodone formulations
|
DE10129725A1
(de)
|
2001-06-20 |
2003-01-02 |
Bayer Ag |
Kombinationstherapie substituierter Oxazolidinone
|
DE10300111A1
(de)
|
2003-01-07 |
2004-07-15 |
Bayer Healthcare Ag |
Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
|
US10213387B2
(en)
|
2003-09-19 |
2019-02-26 |
Sun Pharma Advanced Research Company Ltd. |
Oral drug delivery system
|
EP1663175B1
(en)
*
|
2003-09-19 |
2012-03-28 |
Sun Pharma Advanced Research Company Limited |
Oral drug delivery system
|
US10226428B2
(en)
|
2003-09-19 |
2019-03-12 |
Sun Pharma Advanced Research Company Ltd. |
Oral drug delivery system
|
DE10355461A1
(de)
|
2003-11-27 |
2005-06-23 |
Bayer Healthcare Ag |
Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
|
DE102004062475A1
(de)
*
|
2004-12-24 |
2006-07-06 |
Bayer Healthcare Ag |
Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
|
EP1685841A1
(en)
|
2005-01-31 |
2006-08-02 |
Bayer Health Care Aktiengesellschaft |
Prevention and treatment of thromboembolic disorders
|
DE102005031577A1
(de)
|
2005-07-06 |
2007-01-11 |
Bayer Healthcare Ag |
Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
|
DE102005045518A1
(de)
|
2005-09-23 |
2007-03-29 |
Bayer Healthcare Ag |
2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
|
NZ567092A
(en)
|
2005-10-04 |
2011-05-27 |
Bayer Schering Pharma Ag |
Novel polymorphous form and the amorphous form of 5-chloro-N-({ (5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
|
DE102005047561A1
(de)
|
2005-10-04 |
2007-04-05 |
Bayer Healthcare Ag |
Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
|
DE102008059206A1
(de)
|
2008-11-27 |
2010-06-10 |
Bayer Schering Pharma Aktiengesellschaft |
Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
|
CN102573811A
(zh)
*
|
2009-06-02 |
2012-07-11 |
陶氏环球技术有限责任公司 |
缓释剂型
|
DE102011007272A1
(de)
|
2011-04-13 |
2012-10-18 |
Bayer Pharma Aktiengesellschaft |
Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
|
AU2013258273A1
(en)
|
2012-05-07 |
2014-11-13 |
Bayer Pharma Aktiengesellschaft |
Process for manufacturing a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil
|
UY34856A
(es)
|
2012-07-03 |
2013-12-31 |
Bayer Pharma AG |
Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida
|
JP5941117B2
(ja)
*
|
2014-10-17 |
2016-06-29 |
ダウ グローバル テクノロジーズ エルエルシー |
徐放製剤
|
US10905667B2
(en)
|
2018-07-24 |
2021-02-02 |
Bayer Pharma Aktiengesellschaft |
Orally administrable modified-release pharmaceutical dosage form
|
WO2020020790A1
(de)
|
2018-07-24 |
2020-01-30 |
Bayer Aktiengesellschaft |
Oral applizierbare pharmazeutische darreichungsform mit modifizierter freisetzung
|
EP3826627B1
(de)
|
2018-07-24 |
2023-10-18 |
Bayer Aktiengesellschaft |
Oral applizierbare pharmazeutische darreichungsform mit modifizierter freisetzung
|